UPSTAZA Solution for infusion Ref.[50861] Active ingredients: Eladocagene exuparvovec

Source: European Medicines Agency (EU)  Revision Year: 2023  Publisher: PTC Therapeutics International Limited, 70 Sir John Rogersons Quay, Dublin 2, Ireland

Product name and form

Upstaza 2.8 × 1011 vector genomes (vg)/0.5 mL solution for infusion.

Pharmaceutical Form

Solution for infusion.

Following thaw from frozen, the solution for infusion is a clear to slightly opaque, colourless to faint-white liquid.

Qualitative and quantitative composition

Eladocagene exuparvovec is a gene therapy medicinal product that expresses the human aromatic L-amino acid decarboxylase enzyme (hAADC). It is a non-replicating recombinant adeno-associated virus serotype 2 (AAV2) based vector containing the cDNA of the human dopa decarboxylase (DDC) gene under the control of the cytomegalovirus immediate-early promoter.

Eladocagene exuparvovec is produced in human embryonic kidney cells by recombinant DNA technology.

Each single-dose vial contains 2.8 × 1011 vg of eladocagene exuparvovec in 0.5 extractable mL of solution. Each mL of solution contains 5.6 × 1011 vg of eladocagene exuparvovec.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Eladocagene exuparvovec

Eladocagene exuparvovec is a gene therapy based on recombinant AAV2 vector containing the human cDNA for the DDC gene. After infusion into the putamen, the product results in the expression of the AADC enzyme and subsequent production of dopamine, and consequently, development of motor function in treated AADC-deficient patients.

List of Excipients

Potassium chloride
Sodium chloride
Potassium dihydrogen phosphate
Disodium hydrogen phosphate
Poloxamer 188
Water for injections

Pack sizes and marketing

Type I borosilicate glass vial, with a siliconised chlorobutyl stopper with coating sealed with an aluminium/plastic cap.

Pack size of one vial.

Marketing authorization holder

PTC Therapeutics International Limited, 70 Sir John Rogerson’s Quay, Dublin 2, Ireland

Marketing authorization dates and numbers

EU/1/22/1653/001

Date of first authorisation: 18 July 2022

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.